Our Current Clinical Trials
We’re actively recruiting patients to participate in clinical trials to evaluate our therapeutic candidates. If you believe you or a loved one might be a good candidate for our trials, we encourage you to reach out directly via the link below.
Expanded Access Policy
Ozekibart (INBRX-109) is a precisely engineered tetravalent sdAb-based therapeutic candidate that agonizes DR5 to induce tumor selective programmed cell death.
The Phase 1 trial for Ozekibart (INBRX-109) is currently enrolling combination treatment cohorts in pancreatic adenocarcinoma, malignant pleural mesothelioma, Ewing sarcoma, and colorectal cancer.
The Phase 2 trial for Ozekibart (INBRX-109) is currently enrolling patients with unresectable or metastatic conventional chondrosarcoma.
Learn more Phase 1 Trial Phase 2 Trial
INBRX-106
Our Hexavalent OX40 Agonist
INBRX-106 is a hexavalent sdAb-based therapeutic candidate targeting OX40, which is currently being evaluated in patients with locally advanced or metastatic solid tumors. Signaling through OX40 provides co-stimulation that promotes T-cell expansion, enhanced effector function and memory cell formation, and prevents activation-induced cell death.
Parts 2 and 4, single agent dose expansion and dose expansion in combination with Keytruda, are currently enrolling in the following tumor types:
- Solid Tumors
- Non-Small Cell Lung Cancer (NSCLC)
- Melanoma
- Head and Neck Cancer
- Gastric Cancer (GIST)
- Renal Cell Carcinoma (RCC)
- Urothelial Carcinoma